Modality
ASO
MOA
USP1i
Target
PARP
Pathway
Neuroinflam
SCD
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Mar 2026
Phase 2Current
NCT03766445
1,883 pts·SCD
2019-08→2026-03·Active
1,883 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-162w agoPh2 Data· SCD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2
Active
Catalysts
Ph2 Data
2026-03-16 · 2w ago
SCD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03766445 | Phase 2 | SCD | Active | 1883 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |